This clinical trial is focused on studying a type of breast cancer known as Triple Negative Breast Cancer (TNBC). This form of cancer is characterized by the absence of three common receptors known to fuel most breast cancer growths. The study will explore the effectiveness of a combination of treatments, specifically Sacituzumab Govitecan and Pembrolizumab, compared to other treatments chosen by doctors. Sacituzumab Govitecan is a type of medication called an antibody-drug conjugate, which is designed to target and kill cancer cells. Pembrolizumab is a monoclonal antibody that helps the immune system detect and fight cancer cells.
The purpose of this study is to compare how well patients do without the cancer coming back after receiving these treatments. Participants in the study will be randomly assigned to receive either the combination of Sacituzumab Govitecan and Pembrolizumab or a treatment chosen by their doctor. The study will follow participants over a period of time to monitor their health and any changes in their condition. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments being studied.
Throughout the study, participants will receive regular check-ups and monitoring to ensure their safety and to track the progress of their treatment. The study aims to provide valuable information on the effectiveness of these treatments in preventing the return of cancer in patients with Triple Negative Breast Cancer who have already undergone surgery and initial therapy. This research could potentially lead to new treatment options for patients with this challenging form of breast cancer.
1joining the study
Upon joining the study, you will be randomly assigned to one of two groups. One group will receive a combination of sacituzumab govitecan and pembrolizumab, while the other group will receive a treatment chosen by your doctor.
You will be informed about the specific treatment plan you will follow, including the medications, their dosages, and the schedule for taking them.
2treatment administration
If you are in the group receiving sacituzumab govitecan and pembrolizumab, you will receive these medications through an intravenous infusion. This means the medication will be given directly into your vein.
Sacituzumab govitecan is administered as a 200 mg solution for infusion, and pembrolizumab is given as a 25 mg/mL concentrate for infusion. The exact schedule and frequency will be explained to you by the medical team.
3oral medication
If your treatment plan includes capecitabine, you will take this medication orally in the form of 500 mg film-coated tablets.
The dosage and frequency of capecitabine will be determined by your doctor based on your specific needs and condition.
4monitoring and follow-up
Throughout the study, regular monitoring will be conducted to assess your health and the effectiveness of the treatment. This may include physical exams, blood tests, and imaging studies.
You will be required to attend scheduled follow-up visits to ensure your safety and to track the progress of your treatment.
5completion of the study
At the end of the study period, a final evaluation will be conducted to assess the outcomes of the treatment.
You will receive information about the results of the study and any further steps or treatments that may be recommended based on your condition.
Who Can Join the Study?
Patients must be 18 years of age or older and able to understand and give written consent to participate.
Patients must have a performance status score of 0 or 1, which means they are fully active or have some symptoms but do not need bed rest during the day.
Patients must have a history of Triple Negative Breast Cancer (TNBC) with certain stages and confirmed by a doctor. TNBC is a type of breast cancer that does not have certain receptors. Patients should have remaining cancer in the breast or lymph nodes after initial treatment and surgery. There should be no signs of cancer spread to other parts of the body.
Patients must have received neoadjuvant chemotherapy, which is treatment given before surgery, for at least 6 cycles or 18 weeks. This treatment may include specific drugs like taxane, anthracycline, or pembrolizumab.
Patients must have had adequate surgery to remove all visible cancer in the breast and/or lymph nodes. This includes either a total mastectomy or breast-conserving surgery with no cancer at the edges of the removed tissue. If cancer is found at the edges, more surgery may be needed.
Patients must have received appropriate radiotherapy and recovered before starting the study treatment. This includes radiation to the whole breast or chest wall and possibly the regional lymph nodes, depending on the initial cancer stage.
Patients must have adequate liver function, meaning their liver is working well enough to participate in the study.
Who Cannot Join the Study?
Patients who do not have Triple Negative Breast Cancer cannot participate.
Only female patients can participate; male patients are excluded.
Patients who are not within the specified age range cannot participate. The age range is not specified here, but it is important to check if you meet the age criteria.
Patients who are part of a vulnerable population may be excluded. This typically refers to groups who may need special protection or care.
Sacituzumab Govitecan is a type of medication used in cancer treatment. It is designed to target and attach to specific proteins found on cancer cells, helping to deliver a powerful drug directly to the cancer cells. This can help to kill the cancer cells while causing less harm to normal cells in the body.
Pembrolizumab is a medication that helps the immune system fight cancer. It works by blocking a specific protein that prevents the immune system from attacking cancer cells. By blocking this protein, pembrolizumab allows the immune system to better recognize and destroy cancer cells.
Triple Negative Breast Cancer – Triple Negative Breast Cancer is a type of breast cancer that lacks three common receptors known to fuel most breast cancer growth: estrogen, progesterone, and the HER-2/neu gene. This absence makes it distinct from other breast cancer types, as it does not respond to hormonal therapy or therapies that target HER-2 receptors. The disease often progresses more aggressively than other types of breast cancer. It can spread to other parts of the body, including the lymph nodes, lungs, liver, and brain. The progression involves the growth of cancerous cells in the breast tissue, which can invade surrounding tissues and organs. This type of cancer is more likely to occur in younger women and those with a BRCA1 gene mutation.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Belgium 
France 
Germany 
Ireland 
Italy 
Spain